specific capsular substance

(redirected from pneumococcal polysaccharide)

spe·cif·ic cap·su·lar sub·stance

a soluble type-specific polysaccharide produced during active growth of virulent pneumococci comprising a large part of the capsule.
Mentioned in ?
References in periodicals archive ?
It has also been approved to be concomitantly administered with pneumococcal polysaccharide vaccines in people aged 50 years and above.
The currently recommended prime-boost vaccination strategy using a dose of PCV13 [13-valent pneumococcal conjugate vaccine] followed by a dose of PPV23 [23-valent pneumococcal polysaccharide vaccine] might be a possible way of enhancing the vaccine immunogenicity in immuno-suppressed patients," Dr.
Contract award notice: Provision of pneumococcal polysaccharide vaccine 23-valent for 2017
Experts recommend that anyone over age 65 receive the pneumococcal conjugate vaccine (Prevnar 13[R]) in addition to the pneumococcal polysaccharide vaccine (Pneumovax[R]).
On September 19, 2014, CDC published the Advisory Committee on Immunization Practices (ACIP) recommendation for the routine use of 13-valent pneumococcal conjugate vaccine (PCV13) among adults aged [greater than or equal to] 65 years, to be used in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) (1).
The 23-valent pneumococcal polysaccharide vaccine (PPV23) has been recommended for persons in clinically defined risk groups [greater than or equal to] 2 years of age since 1992 and for all persons [greater than or equal to] 65 years of age since 2003 (1).
Additionally, PCV13 and the pneumococcal polysaccharide vaccine (PPSV23) should not be administered together.
Another noteworthy change is in the amount of time recommended between receiving the 13-valent pneumococcal conjugate vaccine (PCV13) and the subsequent 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults aged 65 years and older who are deemed "immunocompetent.
All adults age 65 years and older should now receive the 13-valent pneumococcal conjugate vaccine (PCV13) in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23) to protect against pneumococcal infection, according to the Centers for Disease Control and Preventions (CDC) Advisory Committee on Immunization Practices (ACIP).
According to CDC (2010) recommendations, patients at high risk for pneumococcal disease with chronic illness, such as renal failure, should receive the pneumococcal polysaccharide vaccine (Pneumovax[R] 23).
The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended in all adults aged 65 years and older and is recommended in those adults younger than 65 years with certain medical conditions displayed in the list below [2].
The second type, pneumococcal polysaccharide vaccine, is available to those over the age of 65 and anyone over the age of two who falls into a high-risk category.

Full browser ?